Abstract: The present invention provides a breast cancer marker selected from the group consisting of fucosylated hornerin, fucosylated Zn-?-2-glycoprotein, fucosylated Ig ?-1 chain C region, and fucosylated desmoplakin; a method for determining breast cancer comprising detecting the breast cancer marker in a sample, and determining on the basis of the results of the results; and a kit to be used for the determination.

Abstract: The present invention relates to: a breast cancer marker which is selected from the group consisting of carboxypeptidase N subunit 2, extracellular matrix protein 1, serum amyloid P component, nebulin, complement component C8 ? chain, apolipoprotein L1, flavin reductase, catalase, carbonic anhydrase 2, apolipoprotein C—I, nuclear pore glycoprotein 210, superoxide dismutase [Cu—Zn], bisphosphoglycerate mutase, carbonic anhydrase 1 and peroxiredoxin-2; a method for determining breast cancer, which comprises detecting the breast cancer marker in a sample and determining breast cancer on the basis of the results of the detection; and a kit for use in the method.

Abstract: A cancer determination apparatus (1) includes a Betti number calculation section (42) for calculating, in a captured image (i) in which a tissue is captured and (ii) which has been binarized by use of a prescribed reference value as a threshold, (I) the number of connected components and (II) the number of spaces, each of the connected components being an aggregate of at least one component which is defined by connecting an outer edge(s) of the at least one component which is a graphic having a closed outer edge, each of the spaces being surrounded by an outer edge(s) of the at least one component, a comparison value calculation section (43) for calculating a comparison value indicating a difference between the number of connected components and the number of spaces, and a determination section (44) for determining, by comparing the comparison value thus calculated with a predetermined reference value, whether or not an image of a cancer tissue is included in the captured image.

Abstract: It is found that a SVVYGLR peptide (SEQ ID NO: 1) can promote proliferation of mesenchymal cells such as marrow-derived mesenchymal stem cells and dental pulp cells. A carbonate apatite-collagen sponge containing the SVVYGLR peptide (SEQ ID NO: 1) is useful as a biomaterial for the regeneration of bone marrow or dental pulp. It becomes possible to provide a skeletal system biomaterial which is capable of promoting the proliferation of the mesenchymal cells and is useful as artificial bone marrow or artificial dental pulp for repairing a defect in a bone marrow tissue or a dental pulp tissue.

Abstract: A cancer determination apparatus (1) includes a Betti number calculation section (42) for calculating, in a captured image (i) in which a tissue is captured and (ii) which has been binarized by use of a prescribed reference value as a threshold, (I) the number of connected components and (II) the number of spaces, each of the connected components being an aggregate of at least one component which is defined by connecting an outer edge(s) of the at least one component which is a graphic having a closed outer edge, each of the spaces being surrounded by an outer edge(s) of the at least one component, a comparison value calculation section (43) for calculating a comparison value indicating a difference between the number of connected components and the number of spaces, and a determination section (44) for determining, by comparing the comparison value thus calculated with a predetermined reference value, whether or not an image of a cancer tissue is included in the captured image.

Abstract: It is found that a SVVYGLR peptide (SEQ ID NO: 1) can promote proliferation of mesenchymal cells such as marrow-derived mesenchymal stem cells and dental pulp cells. A carbonate apatite-collagen sponge containing the SVVYGLR peptide (SEQ ID NO: 1) is useful as a biomaterial for the regeneration of bone marrow or dental pulp. It becomes possible to provide a skeletal system biomaterial which is capable of promoting the proliferation of the mesenchymal cells and is useful as artificial bone marrow or artificial dental pulp for repairing a defect in a bone marrow tissue or a dental pulp tissue.

Abstract: The present invention provides a tumor marker and a method capable of identifying the morbidity of colon cancer. A tumor marker including a protein identified from a colon cancer tissue. A method for identify the morbidity of colon cancer using the tumor marker. The method includes: measuring the level of the protein in a sample derived from a person of interest who should be examined to identify the morbidity of colon cancer; and comparing the measured level to the normal level of the protein, wherein a higher or lower measured level than the normal level is used as one indicator indicating that there is a high possibility that the person of interest has colon cancer.

Abstract: The object of the present invention is to provide a novel marker for a correct diagnosis of lymph node metastasis of breast cancer. This object is attained by a marker for judging lymph node metastasis of tumor cells derived from breast cancer, the marker including mRNA of the gene encoding Forkhead box A1 (FOXA1) or a fragment thereof.

Abstract: A novel angiogenesis drug which can be clinically used for therapies of human or the like is disclosed. The angiogenesis drug according to the present invention comprises a peptide as an effective component, which has a prescribed amino acid sequence and has an angiogenesis action.

Abstract: A novel angiogenesis drug which can be clinically used for therapies of human or the like is disclosed. The angiogenesis drug according to the present invention comprises a peptide as an effective component, which has a prescribed amino acid sequence and has an angiogenesis action.